HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biden Joins House And Senate Asking For FDA's Attention On Making Hearing Aids Available OTC

Executive Summary

One of 72 items in an executive order by the president on promoting competition in the economy notes that 14% of the around 48m US consumers with hearing loss use hearing aids because, on average, they cost more than $5,000 per pair, costs often not covered by health insurance.

You may also be interested in...



‘Revolutionaries’ At FTC Could Give Businesses ‘Very Rough Ride,’ Former Agency Chairman Says

Recently appointed Chairwoman Lina Khan and other "revolutionaries have firmly taken over,” says former FTC chairman Timothy Muris. FTC’s lobbying to restore authority, which SCOTUS struck down, to impose monetary relief orders against marketers linked to false advertising is an example of agency’s direction.

Eargo's 5th Generation Hearing Aid Available OTC Hailed As 'Most Significant Launch' In Its History

Wells Fargo analyst expects that Eargo’s newly launched hearing aid, Eargo 5, will transform and disrupt the $30bn-plus addressable hearing aid market. 

US House Appropriators Have Little Left To Say About Allowing Cannabinoids In Supplements

Appropriation Committee’s report with FDA’s FY2022 funding bill appears to signal that other than getting something done, members have little to say about establishing lawful use of hemp-derived cannabinoids in non-drug products.

Related Content

Topics

UsernamePublicRestriction

Register

RS151540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel